DOI QR코드

DOI QR Code

Nausea and Vomiting after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis

  • Wang, Shi-Ying (Department of Integrative Oncology, Fudan University Shanghai Cancer Center) ;
  • Zhu, Wen-Hao (Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine) ;
  • Vargulick, Sonya (Department of Pharmacy Practice Faculty, Albany College of Pharmacy and Health Sciences) ;
  • Lin, Sam Bill (Department of Oncology, Shanghai Medical College, Fudan University) ;
  • Meng, Zhi-Qiang (Department of Integrative Oncology, Fudan University Shanghai Cancer Center)
  • Published : 2013.10.30

Abstract

Background: Nausea and vomiting after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) are common in clinical practice, but few studies have reported the incidence and risk factors of such events. Objective: The purpose of this study was to analyze the incidence and risk factors of nausea and vomiting after TACE for HCC. Methods: This study was a single-center retrospective analysis of a prospectively maintained database. Between May 2010 and October 2012, 150 patients with HCC were analyzed for incidence and preprocedural risk factors. Results: The incidence of postembolization nausea and vomiting was 38.8% and 20.9%, respectively, in patients with HCC. Patients who developed nausea had lower levels (<100 IU/L) of serum alkaline phosphatase (ALP) compared to those without nausea ($123.04{\pm}69.38$ vs. $167.41{\pm}138.95$, respectively, p=0.044). Female gender correlated to a higher incidence of nausea as well (p=0.024). Patients who developed vomiting, compared to those who did not, also had lower levels (<100 IU/L) of serum ALP ($112.52{\pm}62.63$ vs. $160.10{\pm}127.80$, respectively, p=0.010), and serum alanine transferase (ALT) ($35.61{\pm}22.87$ vs. $4.97{\pm}29.62$, respectively, p=0.045). There were no statistical significances in the incidences of nausea and vomiting between male patients over 50 years old and female patients who have entered menopause (p=0.051 and p=0.409, respectively). Multivariate analysis by logistic regression analysis demonstrated that female gender and ALP>100 IU/L were the most independent predictive factors of postembolization nausea (odds ratio (OR): 3.271, 95% CI: 1.176-9.103, p=0.023 and OR: 0.447, 95% CI: 0.216-0.927, p=0.030, respectively). ALP>100 IU/L was also the most independent predictive risk factor of postembolization vomiting (OR: 0.389, 95% CI: 0.159-0.952, p=0.039). Conclusions: Postembolizaiton nausea and vomiting are common in patients with HCC. Recognition of the risk factors presented above before TACE is important for early detection and proper management of postembolization nausea and vomiting. Nevertheless, future studies are required.

Keywords

Hepatocellular carcinoma;nausea;vomiting;risk factors;transcatheter arterial chemoembolization

References

  1. Bruix J,Sherman M (2005). Management of hepatoceullular carcinoma. Hepatology, 42, 1208-36. https://doi.org/10.1002/hep.20933
  2. American Cancer Society (2013). Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
  3. Beattie WS, Lindblad T, Buckley DN, Forrest JB (1991). The incidence of postoperative nausea and vomiting in women undergoing laparoscopy is influenced by the day of menstrual-cycle. Can J Anaesth, 38, 298-302. https://doi.org/10.1007/BF03007618
  4. Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30. https://doi.org/10.1016/S0168-8278(01)00130-1
  5. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  6. Coates A, Abraham S, Kaye SB, et al (1983). On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol, 19, 203-8. https://doi.org/10.1016/0277-5379(83)90418-2
  7. Coburn R, Lane J, Harrison K, Hennessey J (1993). Postoperative vomiting factors in IVF patients. Aust N Z J Obstet Gynaecol, 33, 57-60. https://doi.org/10.1111/j.1479-828X.1993.tb02055.x
  8. Dhand S, Gupta R (2011). Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol, 28, 207-11. https://doi.org/10.1055/s-0031-1280666
  9. Forner A, Reig ME, de Lope CR, Bruix J (2010). Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis, 30, 61-74. https://doi.org/10.1055/s-0030-1247133
  10. Han P, Zhang J (2007). Meta-analyses on incidences of common complications of primary liver cancer after transcatheter arterial chemoembolization. Shanghai J Prev Med, 19, 517-9.
  11. Harris H (1990). The human alkaline phosphatases: what we know and what we don't know. Clinica Chimica Acta, 186, 133-50. https://doi.org/10.1016/0009-8981(90)90031-M
  12. Honkavaara P, Lehtinen AM, Hovorka J, Korttila K (1991). Nausea and vomiting after gynecological laparoscopy depends upon the phase of the menstrual-cycle. Can J Anaesth, 38, 876-9. https://doi.org/10.1007/BF03036963
  13. Huppe M, Kemter A, Schmidtke C, Klotz KF (2013). [Postoperative complaints : gender differences in expectations, prevalence and appraisal]. Anaesthesist, 62, 528-36. https://doi.org/10.1007/s00101-013-2182-x
  14. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. https://doi.org/10.1055/s-2007-1007122
  15. Seldinger SI (1953). Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol, 39, 368-76. https://doi.org/10.3109/00016925309136722
  16. Moreno C, Veiga D, Pereira H, Martinho C, Abelha F (2013). Postoperative nausea and vomiting: Incidence, characteristics and risk factors - A prospective cohort study. Rev Esp Anestesiol Reanim, 60, 249-56. https://doi.org/10.1016/j.redar.2013.02.005
  17. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45, 529-38. https://doi.org/10.1016/j.jhep.2006.05.013
  18. Sakamoto I, Aso N, Nagaoki K, et al (1998). Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics, 18, 605-19. https://doi.org/10.1148/radiographics.18.3.9599386
  19. Simurina T, Mraovic B, Skitarelic N, Andabaka T, Sonicki Z (2012). Influence of the menstrual cycle on the incidence of nausea and vomiting after laparoscopic gynecological surgery: a pilot study. J Clin Anesth, 24, 185-92. https://doi.org/10.1016/j.jclinane.2011.07.011
  20. Thompson HJ (1999). The management of post-operative nausea and vomiting. J Adv Nurs, 29, 1130-6. https://doi.org/10.1046/j.1365-2648.1999.00998.x
  21. Watcha MF, White PF (1992). Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology, 77, 162-84. https://doi.org/10.1097/00000542-199207000-00023

Cited by

  1. Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.647
  2. Safety and Efficacy of Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization prior to Major Hepatectomy for Patients with HCC vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.703
  3. Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9635
  4. Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2057
  5. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  6. Analyses of Risk Factors and Preventive Effect of Antiemetics on Vomiting Induced by Therapy with Cisplatin Suspension in Lipiodol for Hepatocellular Carcinoma vol.41, pp.11, 2015, https://doi.org/10.5649/jjphcs.41.768
  7. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.473